Four-year survival and safety analysis from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer

U Ubbelohde, D-Y Oh, A R He, S Qin, L-T Chen, T Okusaka, A Vogel, R Griffin, J Wang, I Xynos, J Valle · Zeitschrift für Gastroenterologie · 2026 · Heft 08 · S. e427-e428